CL2021003170A1 - Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa - Google Patents

Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Info

Publication number
CL2021003170A1
CL2021003170A1 CL2021003170A CL2021003170A CL2021003170A1 CL 2021003170 A1 CL2021003170 A1 CL 2021003170A1 CL 2021003170 A CL2021003170 A CL 2021003170A CL 2021003170 A CL2021003170 A CL 2021003170A CL 2021003170 A1 CL2021003170 A1 CL 2021003170A1
Authority
CL
Chile
Prior art keywords
histone deacetylase
methods
deacetylase inhibitors
associated cancers
treating virus
Prior art date
Application number
CL2021003170A
Other languages
English (en)
Inventor
Robert Mcrae
Gail L Brown
Xiaohu Deng
David Slack
Marshelle Smith Warren
Richard Trauger
Original Assignee
Viracta Subsidiary Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viracta Subsidiary Inc filed Critical Viracta Subsidiary Inc
Publication of CL2021003170A1 publication Critical patent/CL2021003170A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen ciertos montos y calendarios de dosificación que evitan y gestionan de manera eficaz los efectos colaterales asociados con el tratamiento con inhibidores de la histona deacetilasa. Opcionalmente, estos calendarios y regímenes de dosificación incluyen tratamiento con un agente antiviral.
CL2021003170A 2019-05-31 2021-11-29 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa CL2021003170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855454P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
CL2021003170A1 true CL2021003170A1 (es) 2022-07-15

Family

ID=73552282

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003170A CL2021003170A1 (es) 2019-05-31 2021-11-29 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Country Status (5)

Country Link
AR (1) AR119033A1 (es)
CL (1) CL2021003170A1 (es)
TW (1) TW202110452A (es)
UY (1) UY38720A (es)
WO (1) WO2020243326A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202134232A (zh) 2019-12-05 2021-09-16 美商維拉克塔治療公司 Hdac抑制劑固態形式
WO2022094122A1 (en) 2020-10-28 2022-05-05 Viracta Subsidiary, Inc. Hdac inhibitor solid state forms
WO2024086688A1 (en) * 2022-10-21 2024-04-25 Viracta Subsidiary, Inc. Dosing methods for hdac inhibitor compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
JP7366385B2 (ja) * 2015-06-19 2023-10-23 トラスティーズ オブ ボストン ユニバーシティ ヘルペスウイルス誘発疾患の処置のための方法および組成物

Also Published As

Publication number Publication date
WO2020243326A1 (en) 2020-12-03
AR119033A1 (es) 2021-11-17
TW202110452A (zh) 2021-03-16
UY38720A (es) 2020-12-31

Similar Documents

Publication Publication Date Title
CL2021003170A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
DOP2020000209A (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2017002904A1 (es) Métodos y kits para tratar la depresión
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2018002344A (es) Metodo para tratar el cancer.
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
BR112017018198A2 (pt) inibição da atividade de olig2
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
MX2021014639A (es) Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.